“This update was constructed using the most recent peer-reviewed, evidence-based literature supplemented by expert consensus opinion to help clinicians best utilize immunotherapy to treat their patients with melanoma," said Howard L. Kaufman, MD, FACS.
MILWAUKEE, Wisc. (PRWEB) May 30, 2018
Following significant scientific and clinical treatment advances in recent years, the Society for Immunotherapy of Cancer (SITC) updated its first-of-its-kind, evidence-based consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma. The update was published Wednesday in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal.
“An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0,” authored under the guidance of the SITC Cancer Immunotherapy Guidelines Cutaneous Melanoma Subcommittee, highlights the many changes to the immunotherapy treatment landscape in melanoma since the original manuscript was published in 2013 in Nature Reviews Clinical Oncology.
“Immunotherapy treatment for patients with cutaneous melanoma has been rapidly evolving since the original inception and publication of these guidelines,” said SITC Immediate Past President Howard L. Kaufman, MD, FACS, who is Chair of the SITC Cancer Immunotherapy Guidelines Cutaneous Melanoma Subcommittee. “This update was constructed using the most recent peer-reviewed, evidence-based literature supplemented by expert consensus opinion to help clinicians best utilize immunotherapy to treat their patients with melanoma.”
The updated SITC manuscript includes consensus expert recommendations on the expanded use of U.S. Food and Drug Administration-approved immune checkpoints inhibitors across all stages of disease, as well as appropriate immunotherapies in the adjuvant setting. Additionally, consensus statements regarding the management of immune-related adverse events and the use of predictive biomarkers are also included to better inform clinicians about all aspects of patient management during an immunotherapy treatment plan.
“It is exciting to see this clinical update come to fruition in melanoma, which originally launched this important series of SITC immunotherapy guidelines,” said SITC President Lisa H. Butterfield, PhD. “With several new Cancer Immunotherapy Guidelines in development and multiple updates to previously published guidelines in progress, SITC is leading clinician education in the constantly evolving fields of cancer immunotherapy and tumor immunology.”
The SITC Cancer Immunotherapy Guidelines are a collection of unbiased consensus statements developed by leading experts to help oncologists determine when and how to best use immunotherapy to treat their patients. Beyond cutaneous melanoma, Cancer Immunotherapy Guidelines for the treatment of renal cell carcinoma, prostate carcinoma, bladder carcinoma and hematologic malignancies have been published in JITC. New treatment guidelines for non-small cell lung cancer, head and neck cancers and acute leukemia are expected to be published by SITC in the next year.
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer reviewed journal of the Society for Immunotherapy of Cancer. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles make JITC the leading forum for tumor immunology and cancer immunotherapy research.
# # #